Work

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

Year: 1997

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: PubMed

Authors: N C Bodick, W W Offen, H E Shannon, J Satterwhite, R Lucas, R van Lier, S M Paul

Institution: Eli Lilly (United States)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2418683731

FWCI: 0.932

Cites:

Cited by: 114

Related to: 10